Literature DB >> 12376616

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

William Dauer1, Nikolai Kholodilov, Miquel Vila, Anne-Cecile Trillat, Rose Goodchild, Kristin E Larsen, Roland Staal, Kim Tieu, Yvonne Schmitz, Chao Annie Yuan, Marcelo Rocha, Vernice Jackson-Lewis, Steven Hersch, David Sulzer, Serge Przedborski, Robert Burke, Rene Hen.   

Abstract

Parkinson's disease (PD) is most commonly a sporadic illness, and is characterized by degeneration of substantia nigra dopamine (DA) neurons and abnormal cytoplasmic aggregates of alpha-synuclein. Rarely, PD may be caused by missense mutations in alpha-synuclein. MPTP, a neurotoxin that inhibits mitochondrial complex I, is a prototype for an environmental cause of PD because it produces a pattern of DA neurodegeneration that closely resembles the neuropathology of PD. Here we show that alpha-synuclein null mice display striking resistance to MPTP-induced degeneration of DA neurons and DA release, and this resistance appears to result from an inability of the toxin to inhibit complex I. Contrary to predictions from in vitro data, this resistance is not due to abnormalities of the DA transporter, which appears to function normally in alpha-synuclein null mice. Our results suggest that some genetic and environmental factors that increase susceptibility to PD may interact with a common molecular pathway, and represent the first demonstration that normal alpha-synuclein function may be important to DA neuron viability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376616      PMCID: PMC137916          DOI: 10.1073/pnas.172514599

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.

Authors:  F J Lee; F Liu; Z B Pristupa; H B Niznik
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

2.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining.

Authors:  N A Tatton; S J Kish
Journal:  Neuroscience       Date:  1997-04       Impact factor: 3.590

3.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

4.  Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines.

Authors:  K B Burrows; W L Nixdorf; B K Yamamoto
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

5.  Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells.

Authors:  J F Reinhard; E J Diliberto; O H Viveros; A J Daniels
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

6.  Targeted oncogene activation by site-specific recombination in transgenic mice.

Authors:  M Lakso; B Sauer; B Mosinger; E J Lee; R W Manning; S H Yu; K L Mulder; H Westphal
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

7.  Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro.

Authors:  N Nakao; K Nakai; T Itakura
Journal:  Brain Res       Date:  1997-11-28       Impact factor: 3.252

8.  Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation.

Authors:  B Ferger; O Eberhardt; P Teismann; C de Groote; J B Schulz
Journal:  J Neurochem       Date:  1999-09       Impact factor: 5.372

9.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

10.  MPTP, MPP+ and mitochondrial function.

Authors:  W J Nicklas; S K Youngster; M V Kindt; R E Heikkila
Journal:  Life Sci       Date:  1987-02-23       Impact factor: 5.037

View more
  206 in total

1.  SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.

Authors:  Pablo Garcia-Reitböck; Oleg Anichtchik; Arianna Bellucci; Mariangela Iovino; Chiara Ballini; Elena Fineberg; Bernardino Ghetti; Laura Della Corte; PierFranco Spano; George K Tofaris; Michel Goedert; Maria Grazia Spillantini
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

2.  Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Authors:  Kavita Prasad; Elizabeth Tarasewicz; Pamela A Ohman Strickland; Michael O'Neill; Stephen N Mitchell; Kalpana Merchant; Samnang Tep; Kathryn Hilton; Akash Datwani; Manuel Buttini; Sarah Mueller-Steiner; Eric K Richfield
Journal:  Eur J Neurosci       Date:  2011-01-28       Impact factor: 3.386

Review 3.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

Review 4.  Etiology of Parkinson's disease: Genetics and environment revisited.

Authors:  Kathy Steece-Collier; Eleonora Maries; Jeffrey H Kordower
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

Review 5.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

Review 6.  The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration.

Authors:  Ai Yamamoto; Anne Simonsen
Journal:  Neurobiol Dis       Date:  2010-08-20       Impact factor: 5.996

7.  Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.

Authors:  Wai Haung Yu; Yasuji Matsuoka; István Sziráki; Audrey Hashim; John Lafrancois; Henry Sershen; Karen E Duff
Journal:  Neurochem Res       Date:  2007-11-13       Impact factor: 3.996

Review 8.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 10.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.